No image published for this recall

No image published for this recall

Blood group reagent anti-lea (murine monoclonal)bioclone

Official notice

11 Jul 2022

Last checked

11 Jul 2022

Medium riskHealth Canada

An official Health Canada notice concerns Blood group reagent anti-lea (murine monoclonal)bioclone. During an internal investigation, Ortho identified that the Anti-Lea (Anti-Le1) lot LAB170A was demonstrating weak to no reactivity with Lea positive cells. The results of the investigation demonstrated that lot LAB170A was more than two dilutions lower than the control lot, thereby these lots were failing internal testing. This issue of weak/no reactivity of Anti-Lea (Anti-Le1) antisera may be detectable in both quality control (QC) and patient samples based on weakened strength of reactivity. Recall start date: June 29, 2022 Published 2022-07-11.

What to do now

Contact the manufacturer if you require additional information.

Recall number

64355

Official notice

2022-07-11

The hazard

During an internal investigation, Ortho identified that the Anti-Lea (Anti-Le1) lot LAB170A was demonstrating weak to no reactivity with Lea positive cells. The results of the investigation demonstrated that lot LAB170A was more than two dilutions lower than the control lot, thereby these lots were failing internal testing. This issue of weak/no reactivity of Anti-Lea (Anti-Le1) antisera may be detectable in both quality control (QC) and patient samples based on weakened strength of reactivity. Recall start date: June 29, 2022

How to check if you're affected

Compare the product name and identifiers below with the item you own. Follow the official notice if they match.

Lots

LAB170A

Recall Numbers

64355

Checked manually this time?

The app alerts you when a new official recall is published — no searching, no checking back.

Turn on recall alerts

Affected products

Product 1

Affected products - Blood Group Reagent Anti-Lea (Murine Monoclonal)Bioclone, Lot or serial number - LAB167A LAB169A LAB168A LAB170A, Model or catalogue number - 715280

Risk / hazard

During an internal investigation, Ortho identified that the Anti-Lea (Anti-Le1) lot LAB170A was demonstrating weak to no reactivity with Lea positive cells. The results of the investigation demonstrated that lot LAB170A was more than two dilutions lower than the control lot, thereby these lots were failing internal testing. This issue of weak/no reactivity of Anti-Lea (Anti-Le1) antisera may be detectable in both quality control (QC) and patient samples based on weakened strength of reactivity. Recall start date: June 29, 2022

Where it was sold

The source does not list specific retailers. See the official notice for where affected products were sold.

Location 1

CA · Canada

Affected area 1

CA · Canada

Company & contacts

Manufacturer

Not provided

Phone

Not provided

Brand: Ortho-clinical Diagnostics, Blood Reagent Anti-leabioclone.

Source & status

Source

Health Canada

Tier

official

Category

HOME

Classification

Type II

App estimate

medium

Recall details

Recall number

64355

Classification

Type II

Source tier

official

Documents, notices & source

See the official notice and source documents for full details.

View full official notice
Something wrong on this page?

Weekly recall digest

Get next week's recalls before you need them.

One email every Monday — official-source recalls for your country, and nothing else. Unsubscribe from any email.

The digest is the slow lane — one email a week. For instant, severity-gated alerts the moment a notice is published, get the app.

This recall was published 11 Jul 2022. The next one won't wait for you to search.

RecallScope watches official sources for the brands and VINs you follow, and alerts you the moment a new notice is published.